Canadian researchers said Wednesday they have developed an antibody treatment that may be able to prevent death from Ebola virus even three full days after infection.
The findings, published in the US journal Science Translational Medicine, suggested that it may be possible to develop a cure for Ebola even after the virus can be detected in the blood and disease symptoms have become apparent, Xinhua reported.
Although rare, Ebola virus is considered one of the most if not the most aggressive virus known to date in part because of its rapidity to kill, which can be within one week from exposure or three to four days from when the first symptoms become apparent.
"For this reason, such a treatment has been considered by many to be closer to the domain of science fiction than contemporary scientific research," said lead author Qiu Xiangguo from the Public Health Agency of Canada.
"This study shows that a way to develop a cure capable of stopping Ebola virus on its track only a few days before death," she added.
The researchers carried out a trial on Ebola-infected monkeys and said they have tentatively scheduled a phase I safety trial, slated for the end of 2014 or early 2015, to test the therapy in humans.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
